Breaking News
1 hour ago
Pharma Now Editorial Team

Pharma Now Editorial Team
Pharma Now Editorial Team
Pharma Now Editorial Team
Pharma Now Editorial Team
FibroBiologics files a USPTO provisional patent for an oral fibroblast delivery platform using multilayer encapsulation and pH-sensitive coatings targeting GI diseases.
Pharma Now Editorial Team

Dogwood Therapeutics opens a 12-week Halneuron® CINP extension study, targeting an end-of-Phase 2 FDA package ahead of a planned 2027 Phase 3 start.
Pharma Now Editorial Team

Medix Biochemica commits $5M to recombinant antigen expansion across Finland and Missouri, targeting 60+ validated products by 2030.
Pharma Now Editorial Team

FDA accepts Viatris NDA for fast-acting meloxicam in acute pain, setting a PDUFA date of December 27, 2026.
Pharma Now Editorial Team